A test kit for detecting HIV drug resistance mutations in patients with low viremia

By designing specific probe combinations and combining melting curve analysis of media probes and detection probes, the problem of difficulty in multiplex detection of HIV drug resistance mutations in existing technologies has been solved, achieving high-sensitivity detection of multiple HIV drug resistance mutation sites, which is suitable for samples with low viral load.

CN123108202APending Publication Date: 2026-11-17XIAMEN UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202611600564.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing HIV drug resistance mutation detection methods are difficult to achieve parallel detection of multiple drug resistance mutation sites in a single reaction, and have insufficient detection capability for samples with low viral load, making them unable to effectively detect low abundance mutations.

Method used

A specific probe combination was designed, including five mediator probes, each targeting a specific HIV drug resistance mutation site. By analyzing the binding and melting curves of the mediator probes and the detection probes, highly sensitive detection of HIV drug resistance mutations was achieved.

Benefits of technology

It enables simultaneous detection of multiple HIV drug resistance mutation sites, improving detection sensitivity and selectivity. It is suitable for samples with low viral load and can accurately identify HIV drug resistance mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108202A_ABST
    Figure CN123108202A_ABST
Patent Text Reader

Abstract

This application relates to the fields of biotechnology and nucleic acid detection. It also relates to a detection reagent for HIV drug resistance mutations suitable for patients with low viremia. Specifically, this application relates to a probe assembly comprising a first, second, third, fourth, and fifth mediator probe, which can simultaneously detect five high-level drug resistance mutations of HIV proteases I47A, I50L, I84V, N88S, and integrase G118R in a single reaction using melting array technology. The probe assembly provided in this application exhibits high sensitivity and specificity, and strong ability to identify low-abundance mutations, making it suitable for detecting HIV drug resistance mutations in samples with low viremia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the fields of biotechnology and nucleic acid detection. Specifically, this application relates to a probe array and a kit containing the probe array, and also to a method for using the probe array to detect the presence of HIV drug resistance gene mutations in biological samples or to detect the level of presence of HIV drug resistance gene mutations. Background Technology

[0002] AIDS, caused by human immunodeficiency virus (HIV), is a serious infectious disease that threatens human health, with HIV-1 being the predominant type. As of 2025, approximately 83.5 million people worldwide have been infected with HIV, and about 43.2 million have died from AIDS-related illnesses. The introduction of Highly Active Antiretroviral Therapy (HAART) in 1996 significantly improved the survival prognosis of AIDS patients and remains the most widely used and effective HIV treatment in clinical practice. However, HAART requires long-term treatment with anti-HIV drugs, leading to a large number of drug-resistant HIV strains in clinical practice. Therefore, selecting appropriate combinations of anti-HIV drugs for HAART treatment has become a key factor in reducing the mortality rate of AIDS patients.

[0003] Low-level viremia (LLV) in HIV-infected individuals is a special population, including untreated patients and some who have failed treatment. Their HIV viral load is low (200-1000 copies / ml) due to the impact of treatment drugs or other reasons. The drug-resistant HIV strains carried by LLV patients are often in a state of co-infection with wild-type HIV strains (i.e., quasi-species infection), and in most cases, the drug-resistant HIV strain is present at low abundance in quasi-species infection. Sanger sequencing is currently the gold standard for HIV genotypic drug resistance detection, with high accuracy in identifying HIV drug resistance mutations. However, its detection sensitivity is between 1000-2000 copies / ml, making it difficult to effectively detect drug resistance mutations carried by LLV patients. Furthermore, Sanger sequencing can only detect drug resistance mutations with an abundance ≥20%, easily missing low-abundance drug-resistant HIV strains. Similarly, NGS technology, also based on sequencing, can detect mutations with abundance as low as 1%, but its application in resource-constrained areas is limited by high cost, long processing time, complex data analysis, lack of standardized procedures, and high dependence on equipment and technical personnel. In addition to sequencing all mutations in the genome, point mutation assays (PMAs) can be developed for certain important drug resistance-associated mutations (DRMs), including allele-specific PCR (AS-PCR), ligation amplification assays (LigAmp), oligonucleotide ligation assays (OLA), RNA amplification one-step ligation assays (LRA), and PANDAA. PMA methods are low-cost, fast, and highly sensitive, making them suitable for point-of-care testing of HIV genotype resistance. However, existing PMA methods are limited in their ability to detect multiple mutations, and the number of mutation sites that can be analyzed per reaction is limited, failing to meet practical testing needs.

[0004] In summary, there are still clear technological gaps in the current field of HIV drug resistance mutation detection: direct sequencing methods, such as Sanger sequencing, are insufficient for detecting low-abundance mutations and samples with low viral loads; while existing high-sensitivity point mutation detection methods struggle to achieve parallel detection of multiple drug resistance mutation sites in a single reaction. Therefore, developing a PCR detection reagent that can simultaneously detect multiple drug resistance mutations in a single tube reaction, possesses both high sensitivity and good versatility, and is suitable for samples with low viral loads, has direct clinical necessity and application value for improving the detection rate of HIV drug resistance mutations in LLV patients and routine clinical samples, and guiding the formulation of individualized antiviral treatment regimens.

[0005] The inventors of this application previously developed a method for the simultaneous detection of multiple target nucleic acid sequences (multiplex detection), which is described in authorized patent ZL201710299957.4. Specifically, this patent discloses a multiplex real-time PCR detection system for detecting target nucleic acid sequences, characterized by using fewer detection probes than the number of target sequences. This multiplex real-time PCR detection system employs a unique detection system: for each target sequence, a non-fluorescently labeled target sequence-specific media probe is designed. Media sub-sequences on multiple media probes can bind and extend with the same fluorescent detection probe, and the extension products have different melting points. Since each media probe corresponds to a target sequence, these target sequences are effectively detected simultaneously using a single fluorescent probe.

[0006] However, due to the high AT content and high variability of the HIV gene sequence, the inventors' team discovered various problems with probes designed targeting HIV drug resistance mutation sites when applying the aforementioned multiplex detection method to detect HIV drug resistance mutations. These problems included weak or absent mutation signal peaks, signal peaks appearing at the target peak for wild-type templates or NTCs, and non-specific signals appearing at non-target peaks. Furthermore, because HIV drug resistance mutation sites are relatively concentrated, the inventors' team found various problems with probe sets designed for combinations of concentrated HIV drug resistance mutation sites when applying the aforementioned multiplex detection method to HIV drug resistance mutations. These problems included overlapping signal peaks, weak signal intensity, and the need for additional signal channels. All of these problems affected the interpretation of results to varying degrees. Therefore, there is a need to provide a highly sensitive and selective reagent for detecting HIV drug resistance mutations in patients with low viremia, in order to accurately detect HIV drug resistance mutations. Summary of the Invention

[0007] To solve the above-mentioned technical problems, the inventors of this application, through extensive experiments and creative work, have for the first time provided a set of probes that can detect specific combinations of HIV drug resistance mutation sites, avoid problems such as overlapping signal peaks and weak signal intensity, and even improve the intensity of positive signals to a certain extent, thereby completing this invention.

[0008] Therefore, in a first aspect, this application provides a probe assembly comprising the following media probes: The first mediator probe has the nucleotide sequence shown in SEQ ID NO: 21; The second medium probe has the nucleotide sequence shown in SEQ ID NO: 31; The third mediator probe has the nucleotide sequence shown in SEQ ID NO: 46; The fourth mediator probe has the nucleotide sequence shown in SEQ ID NO: 57; The fifth medium probe has the nucleotide sequence shown in SEQ ID NO: 69.

[0009] In some embodiments, the mediator probe comprises a mediator subsequence and a target-specific sequence from the 5' to 3' direction, the mediator subsequence comprising a sequence that is not complementary to the target nucleic acid sequence, and the target-specific sequence comprising a sequence that is complementary to the target nucleic acid sequence.

[0010] In some embodiments, the target-specific sequence of the first mediator probe includes a sequence complementary to the region encoding the HIV protease containing the I47A mutation.

[0011] In some embodiments, the target-specific sequence of the second mediator probe includes a sequence complementary to the region encoding the HIV protease containing the I50L mutation.

[0012] In some embodiments, the target-specific sequence of the third mediator probe includes a sequence complementary to the region encoding the HIV protease containing the I84V mutation.

[0013] In some embodiments, the target-specific sequence of the fourth mediator probe includes a sequence complementary to the region encoding the HIV protease containing the N88S mutation.

[0014] In some embodiments, the target-specific sequence of the fifth mediator probe includes a sequence complementary to the region encoding the HIV integrase containing the G118R mutation.

[0015] In some implementations, the probe combination is used to detect whether a subject carries drug-resistant HIV or to detect the level of drug-resistant HIV carried by the subject.

[0016] In some embodiments, the sequence of the HIV protease is as shown in SEQ ID NO: 1. In some embodiments, the nucleotide sequence encoding the HIV protease is as shown in SEQ ID NO: 2.

[0017] In some embodiments, the sequence of the HIV integrase is shown in SEQ ID NO: 3. In some embodiments, the nucleotide sequence encoding the HIV integrase is shown in SEQ ID NO: 4.

[0018] In some implementations, the detection in this application is based on MeltArray melting array technology, combined with PCR and melting curve analysis, and HIV drug resistance mutations are detected by media probes and detection probes.

[0019] The vector probe contains a vector subsequence and a target-specific sequence from the 5' to 3' direction. The target-specific sequence contains a sequence that is completely complementary to the mutant target sequence of the HIV drug resistance mutation site. The vector subsequence contains a sequence that is not complementary to the mutant target sequence. The vector subsequences contained in all vector probes may be different from or the same as each other. Each detection probe independently includes, from the 3' to 5' direction, a capture sequence complementary to or partially complementary to the mediator subsequence, and a template sequence; and the capture sequence is complementary to or partially complementary to the mediator subsequence of the mediator probe; and each detection probe is independently labeled with a reporter group and a quencher group, wherein the reporter group is capable of emitting a signal, and the quencher group is capable of absorbing or quenching the signal emitted by the reporter group; and the signal emitted by each detection probe when hybridizing with its complementary sequence is different from the signal emitted when it does not hybridize with its complementary sequence.

[0020] Therefore, when a mutant target sequence containing a specific HIV drug resistance mutation site is present, both the upstream primer and the mediator probe corresponding to the mutant target sequence hybridize with the target nucleic acid sequence. However, the mediator sequence in the mediator probe remains in a free state and does not hybridize with the target nucleic acid sequence. In this case, under the action of an enzyme with 5' nuclease activity, the mediator sequence or a portion thereof in the mediator probe (the mediator probe corresponding to the target nucleic acid sequence) is cleaved from the mediator probe due to the presence of the upstream primer or its extension product corresponding to the target nucleic acid sequence, forming a mediator fragment corresponding to the target nucleic acid sequence.

[0021] Therefore, when a mediator fragment corresponding to the mutant target sequence is present, the mediator fragment hybridizes with the detection probe, and the nucleic acid polymerase extends the mediator fragment using the detection probe as a template to form a double-stranded structure corresponding to the target nucleic acid sequence. Furthermore, when a melting peak corresponding to a double-stranded structure corresponding to a certain target nucleic acid sequence is detected or not detected, it is determined that the target nucleic acid sequence is present or not present in the sample.

[0022] In some implementations, cleavage of the mediator probe can be induced in two ways: (A) an extension method independent of the upstream primer; and (B) an extension method dependent on the upstream primer. Specifically, after hybridization of the upstream primer and the mediator probe with the target nucleic acid sequence, if the upstream primer and the mediator probe are close enough that an enzyme with 5' nuclease activity can induce cleavage of the mediator probe, then the enzyme will bind to the upstream primer and cleave the mediator probe without an extension reaction (i.e., method A). Conversely, after hybridization with the target nucleic acid sequence, if the upstream primer is far from the mediator probe, then a nucleic acid polymerase is first used, using the target nucleic acid sequence as a template, to catalyze the extension of the upstream primer, followed by an enzyme with 5' nuclease activity binding to the extension product of the upstream primer and cleaving the mediator probe (i.e., method B).

[0023] Taking the first mediator probe as an example, the first mediator probe contains a first mediator subsequence and a first target-specific sequence from the 5' to 3' direction. The first target-specific sequence is complementary to a first region encoding the HIV protease containing the I47A mutation. The first detection probe contains a capture sequence complementary to the first mediator subsequence of the first mediator probe, as well as a template sequence; and the first detection probe is labeled with a reporter group and a quencher group. Therefore, when a mutant target sequence containing the HIV protease I47A mutation is present, the first target-specific sequence of the first mediator probe binds to the target sequence containing the first region of the HIV protease I47A mutation. Under the action of an enzyme with 5' nuclease activity, the first mediator subsequence or a portion thereof in the first mediator probe is cleaved from the first mediator probe due to the presence of the upstream sequence corresponding to the target nucleic acid sequence or its extension product, forming a free first mediator subfraction. Subsequently, the first mediator subfraction hybridizes to the first detection probe and is extended by a nucleic acid polymerase, thereby producing an extension product, which together with the first detection probe forms a double strand with a specific Tm value. The detection mechanisms of the second, third, fourth, and fifth mediator probes are similar to those of the first mediator probe. By distinguishing the Tm of the dipeptides they produce and combining them with their corresponding fluorescence channels, the presence of their corresponding target molecules can be determined.

[0024] It should be understood that the contribution of this application lies at least in providing a set of mediator probes (i.e., probe assemblies) with unique sequences targeting five high-level HIV drug resistance mutation sites of high clinical value. It is important to emphasize that the detection of this probe assemblies does not entirely depend on their use in conjunction with detection probes. That is, even without the use of detection probes, the probe assemblies can independently detect the five high-level HIV drug resistance mutations.

[0025] Although both a mediator probe and a detection probe are used in the embodiments, those skilled in the art can modify the mediator probe appropriately to complete the detection without using the detection probe. For example, a fluorescent group and a quencher group can be directly connected to both ends of the mediator probe to detect HIV drug resistance mutations. In this case, the differences in the thermodynamic properties of nucleic acid hybridization can still accurately distinguish between wild-type target sequences with single-base mismatches and completely complementary HIV mutant target sequences. The presence or absence of melting peaks, characteristic Tm values, and differentiation of fluorescence channels can achieve effective detection of the above five HIV drug resistance mutations.

[0026] Therefore, in some embodiments, in the probe assembly, the first mediator probe, the second mediator probe, the third mediator probe, the fourth mediator probe, and the fifth mediator probe are connected to a fluorescent group and a quenching group; the fluorescent group is capable of emitting a fluorescent signal, and the quenching group is a molecule or group capable of absorbing or quenching the fluorescent signal generated by the fluorescent group; and the signal emitted by the probe when hybridizing with an HIV mutant target sequence is different from the signal emitted when not hybridizing with an HIV mutant target sequence.

[0027] In some embodiments, the fluorescent group is selected from ALEX-350, FAM, VIC, TET, CAL Fluor Gold540, JOE, HEX, CAL Fluor Orange 560, TAMRA, CAL Fluor Red 590, ROX, CAL Fluor Red610, TEXAS RED, CAL Fluor Red 635, Quasar 670, CY3, CY5, CY5.5 and Quasar 705.

[0028] In some embodiments, the quenching group is selected from DABCYL, BHQ (e.g., BHQ-1 or BHQ-2), ECLIPSE, and TAMRA.

[0029] In some embodiments, the fluorescent group of the medium probe is attached to the 5' end of the probe, and the quenching group is attached to the 3' end of the probe.

[0030] In some embodiments, the fluorescent group attached to the first mediator probe is FAM, and the quenching group attached is BHQ1.

[0031] In some embodiments, the second mediator probe is attached to a fluorophore ROX and a quencher group BHQ2.

[0032] In some embodiments, the third mediator probe is attached to a fluorophore HEX and a quencher group BHQ1.

[0033] In some embodiments, the fourth mediator probe is attached to a fluorophore HEX and a quencher group BHQ1.

[0034] In some embodiments, the fifth mediator probe is attached to a fluorescent group of FAM and a quenching group of BHQ1.

[0035] In another aspect, this application provides a kit comprising the probe combination described above.

[0036] In some embodiments, the kit further includes one or more components selected from the following: nucleic acid polymerase, reagents for nucleic acid amplification, reagents for sequencing, reagents for melting curve analysis, or any combination thereof.

[0037] In some embodiments, the reagents used for nucleic acid amplification include working buffers for enzymes (e.g., nucleic acid polymerases), dNTPs (labeled or unlabeled), water, and reagents containing ions (e.g., Mg). 2+ ( ) solutions, single-stranded DNA-binding proteins, or any combination thereof.

[0038] In this application, various enzymes with 5' nuclease activity can be used. In some preferred embodiments, the enzyme with 5' nuclease activity is an enzyme with 5' exonuclease activity. In some embodiments, the enzyme with 5' nuclease activity is a nucleic acid polymerase (e.g., DNA polymerase, particularly a thermostable DNA polymerase) with 5' nuclease activity (e.g., 5' exonuclease activity). In some embodiments, the use of a nucleic acid polymerase with 5' nuclease activity is particularly advantageous because the polymerase can both catalyze the elongation of an upstream oligonucleotide sequence using the target nucleic acid sequence as a template and induce the cleavage of the medium probe.

[0039] In some preferred embodiments, the DNA polymerase having 5' nuclease activity is a thermostable DNA polymerase, which can be obtained from various bacterial species, for example, Thermus aquaticus (Taq), Thermus thermophiles (Tth), Thermus filiformis, Thermis flavus, Thermococcus literalis, Thermus antranildanii, Thermus caldophllus, Thermus chliarophilus, Thermus flavus, Thermus igniterrae, Thermus lacteus, Thermus oshimai, Thermus ruber, Thermus rubens, Thermus scotoductus, Thermus silvanus, Thermus thermophllus, Thermotoga maritima, Thermotoga neapolitana, Thermosipho africanus, Thermococcus litoralis, Thermococcus barossi, Thermococcus gorgonarius, Thermotoga maritima, Thermotoga neapolitana, Thermosiphoafricanus, Pyrococcus woesei, Pyrococcus horikoshii, Pyrococcus abyssi, Pyrodictium occultum, Aquifexpyrophilus and Aquifex aeolieus Particularly preferably, the DNA polymerase with 5' nuclease activity is Taq polymerase.

[0040] In some embodiments, the kit further includes detection probes comprising a capture sequence complementary to a mediator subsequence or a portion thereof of the mediator probe, and a template sequence; and the detection probes are labeled with a reporter group and a quencher group, wherein the reporter group is capable of emitting a signal, and the quencher group is capable of absorbing or quenching the signal emitted by the reporter group; and each detection probe emits a different signal when hybridizing with its complementary sequence than when it does not hybridize with its complementary sequence.

[0041] In addition to the capture sequence and template sequence, the detection probe may also contain an additional sequence at its 3' end (i.e., downstream of the capture sequence). This additional sequence typically contains a sequence that is not complementary to the mediator fragment and does not participate in hybridization with the mediator fragment.

[0042] According to the present invention, the template sequence in the detection probe can contain any sequence and is located upstream (5' end) of each capture sequence, thus serving as a template for extending the mediator fragment. In some embodiments, the template sequence contains a sequence that is not complementary to the mediator probe (mediator fragment sequence and target-specific sequence). Such a template sequence is particularly advantageous in certain situations because it can improve the hybridization specificity of the mediator fragment with the detection probe, preventing the mediator fragment from hybridizing to undesirable locations, thereby avoiding the generation of undesirable double strands.

[0043] In some embodiments, the detection probe is a self-quenching probe; for example, the detection probe is labeled with a reporter group at its 5' end or upstream and with a quenching group at its 3' end or downstream, or with a reporter group at its 3' end or downstream and with a quenching group at its 5' end or upstream.

[0044] The design of such self-quenching detection probes is within the capabilities of those skilled in the art. For example, a reporter group can be labeled at the 5' end of the detection probe and a quencher group at the 3' end, or a reporter group can be labeled at the 3' end of the detection probe and a quencher group at the 5' end. Thus, when the detection probe is present alone, the reporter group and the quencher group approach and interact with each other, causing the signal emitted by the reporter group to be absorbed by the quencher group, thereby preventing the detection probe from emitting a signal; while when the detection probe hybridizes with its complementary sequence, the reporter group and the quencher group separate, preventing the signal emitted by the reporter group from being absorbed by the quencher group, thereby allowing the detection probe to emit a signal.

[0045] In some embodiments, the reporter group and the quencher group are spaced 10-80 nt apart or longer.

[0046] In some embodiments, the reporter group is a fluorescent group.

[0047] In some embodiments, the fluorescent group is selected from ALEX-350, FAM, VIC, TET, CAL Fluor Gold540, JOE, HEX, CAL Fluor Orange 560, TAMRA, CAL Fluor Red 590, ROX, CAL Fluor Red610, TEXAS RED, CAL Fluor Red 635, Quasar 670, CY3, CY5, CY5.5 and Quasar 705.

[0048] In some embodiments, the quenching group is selected from DABCYL, BHQ (e.g., BHQ-1 or BHQ-2), ECLIPSE, and TAMRA.

[0049] Furthermore, various suitable pairings of reporter and quencher groups are known in the art; see, for example, Pesce et al., editors, *Fluorescence Spectroscopy* (Marcel Dekker, New York, 1971); White et al., *Fluorescence Analysis: A Practical Approach* (Marcel Dekker, New York, 1970); Berlman, *Handbook of Fluorescence Spectra of Aromatic Molecules*, 2nd Edition (Academic Press, New York, 1971); Griffiths, *Color AND Constitution of Oiganic Molecules* (Academic Press, New York, 1976); Bishop, editor, Indicators (Peigamon Press, Oxford, 1972); Haugland, *Handbook of Fluorescent Probes and Research Chemicals* (Molecular Probes, Eugene, 1992); Pringsheim, *Fluorescence and Phosphorescence* (Interscience Publishers, New York, 1949). Haugland, RP, Handbook of Fluorescent Probes and Research Chemicals, 6th Edition (Molecular Probes, Eugene, Oreg., 1996); U.S. Patents 3,996,345 and 4,351,760.

[0050] In some embodiments of the invention, the detection probe may comprise or consist of naturally occurring nucleotides (e.g., deoxyribonucleotides or ribonucleotides), modified nucleotides, non-natural nucleotides (e.g., peptide nucleic acids (PNAs) or locked nucleic acids), or any combination thereof. In some preferred embodiments, the detection probe comprises or consists of natural nucleotides (e.g., deoxyribonucleotides or ribonucleotides). In some preferred embodiments, the detection probe comprises modified nucleotides, such as modified deoxyribonucleotides or ribonucleotides, such as 5-methylcytosine or 5-hydroxymethylcytosine. In some preferred embodiments, the detection probe comprises non-natural nucleotides, such as deoxyhypoxanthine, inosine, 1-(2'-deoxy-β-D-furanoribosyl)-3-nitropyrrole, 5-nitroindole, or locked nucleic acids (LNAs).

[0051] When the detection probe exists alone, due to the free curling of the probe molecule or the formation of the probe's secondary structure (e.g., hairpin structure), the reporter group and the quencher group approach and interact with each other, causing the signal emitted by the reporter group to be absorbed by the quencher group, thereby preventing the detection probe from emitting a signal. Conversely, when the detection probe hybridizes with its complementary sequence, the reporter group and the quencher group are separated by a sufficient distance, preventing the signal emitted by the reporter group from being absorbed by the quencher group, thereby allowing the detection probe to emit a signal.

[0052] In some embodiments, the detection probe includes: a first detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the first media probe; a second detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the second media probe; a third detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the third media probe; a fourth detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the fourth media probe; and a fifth detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the fifth media probe.

[0053] In some embodiments, the nucleotide sequence of the first detection probe is as shown in SEQ ID NO: 9 or a variant thereof.

[0054] In some embodiments, the nucleotide sequence of the second detection probe is as shown in SEQ ID NO: 13 or a variant thereof.

[0055] In some embodiments, the nucleotide sequence of the third detection probe is as shown in SEQ ID NO: 11 or a variant thereof.

[0056] In some embodiments, the nucleotide sequence of the fourth detection probe is as shown in SEQ ID NO: 12 or a variant thereof.

[0057] In some embodiments, the nucleotide sequence of the fifth detection probe is as shown in SEQ ID NO: 10 or a variant thereof.

[0058] In some embodiments, the variant has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with the sequence from which it originates.

[0059] In some embodiments, the variant has one, two, three, four, or five nucleotide substitutions, deletions, or additions relative to the sequence from which it originates.

[0060] In some embodiments, the variant has a truncation or extension of one, two, three, four, or five nucleotides at the 5' and / or 3' ends relative to the sequence from which it originates.

[0061] In some implementations, the variant contains degenerate bases or subtype-adaptive bases at non-mutation discriminant sites compared to the sequence from which it originates.

[0062] In some implementations, the variant contains modified nucleotides capable of modulating melting temperature or hybridization stability compared to its derived sequence.

[0063] In some implementations, the variant retains the ability to hybridize with the region containing the corresponding HIV resistance-associated mutation site, compared to the sequence from which it originated.

[0064] In some embodiments, the variant, under the same or substantially the same melting array reaction conditions, has a melting peak Tm that differs from the melting peak of the medium probe shown in the sequence from which it originates by no more than ±3.0°C, preferably no more than ±2.0°C, and more preferably no more than ±1.0°C from the melting peak of the corresponding detection probe.

[0065] In some implementations, the variant is distinguishable from the corresponding wild-type sequence compared to the sequence from which it originates.

[0066] In some embodiments, the nucleotide sequence of the first detection probe is as shown in SEQ ID NO: 9, or a nucleotide sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity with and having the same function as SEQ ID NO: 9.

[0067] In some embodiments, the nucleotide sequence of the second detection probe is as shown in SEQ ID NO: 13, or a nucleotide sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity with and having the same function as SEQ ID NO: 13.

[0068] In some embodiments, the nucleotide sequence of the third detection probe is as shown in SEQ ID NO: 11, or a nucleotide sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity with and having the same function as SEQ ID NO: 11.

[0069] In some embodiments, the nucleotide sequence of the fourth detection probe is as shown in SEQ ID NO: 12, or a nucleotide sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity with and having the same function as SEQ ID NO: 12.

[0070] In some embodiments, the nucleotide sequence of the fifth detection probe is as shown in SEQ ID NO: 10, or a nucleotide sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identity with and having the same function as SEQ ID NO: 10.

[0071] In some implementations, the first detection probe is attached to a fluorescent group of FAM and a quenching group of BHQ1.

[0072] In some embodiments, the fluorescent group attached to the second detection probe is ROX, and the quenching group attached is BHQ2.

[0073] In some embodiments, the third detection probe is attached to a fluorophore HEX and a quencher group BHQ1.

[0074] In some embodiments, the fourth detection probe is attached to a fluorophore HEX and a quencher group BHQ1.

[0075] In some embodiments, the fifth detection probe is attached to a fluorescent group of FAM and a quenching group of BHQ1.

[0076] In some implementations, the kit also contains additional nucleic acid molecules.

[0077] In some embodiments, the additional nucleic acid molecule includes primers for amplifying the target nucleic acid. For example, upstream primers and / or downstream primers.

[0078] In some embodiments, the additional nucleic acid molecule includes primers for amplifying nucleotide sequences of regions containing I47A mutations in HIV proteases, regions containing I50L mutations in HIV proteases, regions containing I84V mutations in HIV proteases, regions containing N88S mutations in HIV proteases, and / or regions containing G118R mutations in HIV integrase.

[0079] In some embodiments, the additional nucleic acid molecule includes primers for amplifying the nucleotide sequence encoding the HIV protease and / or primers for amplifying the nucleotide sequence encoding the HIV integrase.

[0080] In some embodiments, the sequences of the primers used to amplify the nucleotide sequence encoding the HIV protease are as shown in SEQ ID NO: 5 and SEQ ID NO: 6.

[0081] In some embodiments, the sequences of the primers used to amplify the nucleotide sequence encoding the HIV integrase are shown in SEQ ID NO: 7 and SEQ ID NO: 8.

[0082] On the other hand, this application provides a method for detecting the presence of HIV drug resistance gene mutations in a biological sample or detecting the level of presence of HIV drug resistance gene mutations, the method comprising: (a) Provide a biological sample containing a region encoding an I47A mutation in an HIV protease, a region encoding an I50L mutation in an HIV protease, a region encoding an I84V mutation in an HIV protease, a region encoding an N88S mutation in an HIV protease, and / or a region encoding a G118R mutation in an HIV integrase, and amplify the target nucleic acid in the biological sample by PCR reaction under conditions that allow nucleic acid amplification, thereby obtaining an amplification product; (b) Under conditions that allow for the cleavage of the medium probe, contact the product of step (a) with an enzyme having 5' nuclease activity; perform melting curve analysis on the obtained amplification product using the probe combination as described above or the kit as described above; (c) Based on the melting curve analysis results, determine whether there is an HIV drug resistance gene mutation or the level of HIV drug resistance gene mutation.

[0083] It is understood that the method of this application has applications for non-diagnostic and non-therapeutic purposes. For example, the method of this application can be used to assess the drug resistance barrier of anti-HIV drugs or to conduct HIV drug resistance kinetic studies. For example, in the in vitro screening and in vivo efficacy experiments of candidate anti-HIV drugs, this method can be used to periodically detect the occurrence time, enrichment rate and abundance changes of drug resistance mutations in the viral population, assess the level of drug resistance barrier of new drugs, and compare the drug resistance risk of different candidate drugs; for example, when continuously passages HIV virus under in vitro drug stress, the high sensitivity advantage of this method can be used to track the dynamic process of drug resistance mutations gradually enriching from a low abundance of 1% to a dominant strain, and to analyze the occurrence sequence and co-evolutionary rules of drug resistance mutations.

[0084] Therefore, in some embodiments, the method is a non-diagnostic method. In some embodiments, the method is a non-therapeutic method.

[0085] In some implementations, the method is performed by the following steps: (i) Obtain the biological sample and, under conditions that allow nucleic acid amplification, amplify the nucleotide sequence encoding the HIV protease and the nucleotide sequence encoding the HIV integrase by PCR reaction to obtain the amplification product; (ii) Under conditions that allow for the cleavage of the medium probe, the product of step (i) is contacted with an enzyme having 5' nuclease activity; (iii) Under conditions that allow nucleic acid hybridization, the product of step (ii) is contacted with the following media probes and detection probes: the first, second, third, fourth, and fifth media probes as shown in SEQ ID NO: 21, SEQ ID NO: 31, SEQ ID NO: 46, SEQ ID NO: 57, and SEQ ID NO: 69, respectively, and the first, second, third, fourth, and fifth detection probes as defined above. Then, the temperature is gradually increased and the signal emitted by the reporter group on each detection probe is monitored in real time to obtain a curve showing the change in signal intensity of each reporter group as a function of temperature. Then, the curve is differentiated to obtain a melting curve. (iv) Determine whether HIV drug resistance gene mutations are present and the level of HIV drug resistance gene mutations based on the melting peaks in the melting curve.

[0086] In some embodiments, in step (i), primers such as those shown in SEQ ID NO: 5 and SEQ ID NO: 6 are used to amplify the nucleotide sequence encoding the HIV protease to obtain the target nucleic acid.

[0087] In some embodiments, in step (i), primers such as those shown in SEQ ID NO: 7 and SEQ ID NO: 8 are used to amplify the nucleotide sequence encoding HIV integrase to obtain the target nucleic acid.

[0088] In some embodiments, the biological sample is selected from whole blood, serum, plasma, cerebrospinal fluid, sputum, feces, urine, saliva, sweat, tears, lymph, lavage fluid, ascites, milk, amniotic fluid, or any combination thereof.

[0089] In some implementations, the biological sample is derived from a patient with low-level viremia (LVV).

[0090] On the other hand, this application provides the use of the probe combination as described above or the kit as described above in the preparation of reagents for detecting whether a subject carries drug-resistant HIV or detecting the level of drug-resistant HIV carried by the subject; wherein the drug-resistant HIV contains one or more mutations selected from the following: HIV protease mutations I47A, I50L, I84V, N88S and HIV integrase mutation G118R.

[0091] In some implementations, the subject is a mammal (e.g., a human).

[0092] In some implementations, the subject is a patient with low viremia.

[0093] In some embodiments, the reagent is used to perform the method described above.

[0094] Terminology Definition In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the operational steps used herein, such as molecular genetics, nucleic acid chemistry, chemistry, molecular biology, biochemistry, cell culture, microbiology, cell biology, genomics, and recombinant DNA, are all conventional steps widely used in their respective fields. To better understand this invention, definitions and explanations of relevant terms are provided below.

[0095] As used herein, the term "drug resistance" refers to a decreased or lost sensitivity to a drug. The term "HIV drug resistance mutation" refers to a nucleotide mutation in the HIV viral genome that leads to a decreased or complete loss of sensitivity to antiretroviral drugs. The term "drug-resistant HIV" refers to an HIV strain that has decreased or completely lost sensitivity to antiretroviral drugs.

[0096] As used herein, the term "Human Immunodeficiency Virus (HIV)," also known as the AIDS virus, belongs to the genus Lentivirus in the family Retroviridae. Two species of HIV infect humans: HIV-1 and HIV-2. HIV-1 is the most common HIV strain and is known to be more pathogenic than HIV-2. As used herein, the term "HIV" refers to HIV-1 and / or HIV-2.

[0097] As used in this article, the term "HIV protease" refers to the protein encoded by the PR region, the first functional region of the pol gene in the HIV genome. The PR region is a high-risk area for HIV drug resistance mutations. HIV protease contains multiple drug resistance mutation sites, among which I47A, I50L, I84V, and N88S are all high-level drug resistance mutations with a Stanford HIV Resistance Database score of 60. A single mutation at a single site can lead to drug resistance in the strain. For example, the I47A mutation can lead to resistance to lopinavir / ritonavir (LPV / r); the I50L, I84V, and N88S mutations can all lead to resistance to atazanavir / ritonavir (ATV / r) and bitegravir (BIC).

[0098] As used in this article, the term "HIV integrase" is a protein encoded by the INT (Integrase Region), the third functional region of the pol gene in the HIV genome. The HIV integrase mutation G118R is a major INSTI (Integrase Stroke Regulator) resistance mutation recently included by the International Association for Antiretroviral Therapy (IAS-USA), which can lead to resistance to capecitabine (CAB), raltecitabine (RAL), aviravir (EVG), dolutegravir (DTG), and bisacodyl (BIC) in viral strains.

[0099] The twenty common amino acids referred to herein are written in accordance with conventional usage. See, for example, Immunology-ASynthesis (2nd Edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In this invention, the terms “polypeptide” and “protein” have the same meaning and are used interchangeably. Furthermore, in this invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0100] As used herein, the term "mutation" refers to the presence of a missing, added, or substituted amino acid residue in the amino acid sequence of a protein or polypeptide compared to the amino acid sequence of a reference protein or polypeptide. In the specification (particularly the examples), the substitution of an amino acid at a specific position in the protein sequence is expressed as "(amino acid residue in wild-type protein) (amino acid position) (amino acid residue in engineered protein)". For example, "I47A" means that the isoleucine (I) residue at position 47 of the amino acid sequence of the reference protein is replaced by an alanine (A) residue.

[0101] As used herein, the terms “target nucleic acid sequence,” “target nucleic acid,” and “target sequence” refer to the target nucleic acid sequence to be detected. In this application, the terms “target nucleic acid sequence,” “target nucleic acid,” and “target sequence” have the same meaning and are used interchangeably.

[0102] As used herein, the term "mediator probe" refers to a single-stranded nucleic acid molecule containing a mediator sequence and a targeting sequence (i.e., a target-specific sequence) in the 5' to 3' direction. In this application, the mediator sequence does not contain a sequence complementary to the target nucleic acid sequence, and the target-specific sequence contains a sequence complementary to the target nucleic acid sequence. Therefore, under conditions allowing nucleic acid hybridization, annealing, or amplification, the mediator probe hybridizes or anneals to the target nucleic acid sequence via the target-specific sequence (i.e., forming a double-stranded structure), and the mediator sequence in the mediator probe does not hybridize with the target nucleic acid sequence but remains in a free state (i.e., maintaining a single-stranded structure).

[0103] As used herein, the terms "target sequence" and "target-specific sequence" refer to a sequence capable of selectively / specifically hybridizing or annealing with a target nucleic acid sequence under conditions allowing nucleic acid hybridization, annealing, or amplification, and which includes a sequence complementary to the target nucleic acid sequence. In this application, the terms "target sequence" and "target-specific sequence" have the same meaning and are used interchangeably. It is readily understood that a target sequence or target-specific sequence is specific to the target nucleic acid sequence. In other words, under conditions allowing nucleic acid hybridization, annealing, or amplification, the target sequence or target-specific sequence hybridizes or anneals only with the specific target nucleic acid sequence and not with other nucleic acid sequences.

[0104] As used herein, the term "mediator sequence" refers to an oligonucleotide sequence in a mediator probe that is not complementary to the target nucleic acid sequence and is located upstream (5' end) of the target-specific sequence. In this application, a unique mediator probe with a unique mediator sequence is designed or provided for each target nucleic acid sequence (in other words, the mediator sequences in all mediator probes used are different from each other); thus, each target nucleic acid sequence corresponds to a unique mediator probe (the unique mediator sequence). Therefore, by detecting the unique mediator sequence, the corresponding target nucleic acid sequence can be detected.

[0105] As used herein, the term "complementary" means that two nucleic acid sequences are capable of forming hydrogen bonds with each other according to the Waston-Crick principle, thereby forming a double helix. In this application, the term "complementary" includes both "substantially complementary" and "completely complementary." As used herein, the term "completely complementary" means that every base in one nucleic acid sequence is capable of pairing with a base in the other nucleic acid strand without mismatches or gaps. As used herein, the term "substantially complementary" means that a majority of the bases in one nucleic acid sequence are capable of pairing with bases in the other nucleic acid strand, allowing for mismatches or gaps (e.g., mismatches or gaps of one or more nucleotides). Typically, under conditions that allow for nucleic acid hybridization, annealing, or amplification, two "complementary" (e.g., substantially complementary or completely complementary) nucleic acid sequences will selectively / specifically hybridize or anneal and form a double helix. For example, in this application, the target-specific sequences in the vector probe each contain a sequence complementary to (e.g., substantially complementary or completely complementary) the target nucleic acid sequence. Therefore, under conditions that allow nucleic acid hybridization, annealing, or amplification, the target-specific sequence in the vector probe will selectively / specifically hybridize or anneal with the target nucleic acid sequence. Correspondingly, the term "non-complementary" means that two nucleic acid sequences cannot hybridize or anneal under conditions that allow nucleic acid hybridization, annealing, or amplification, and cannot form a double strand. For example, in this application, the vector subsequence contains a sequence that is not complementary to the target nucleic acid sequence. Therefore, under conditions that allow nucleic acid hybridization, annealing, or amplification, the vector subsequence does not hybridize or anneal with the target nucleic acid sequence, cannot form a double strand, and remains in a free state (i.e., retains a single-stranded structure).

[0106] As used herein, the terms “hybridization” and “annealing” refer to the process by which complementary single-stranded nucleic acid molecules form double-stranded nucleic acids. In this application, “hybridization” and “annealing” have the same meaning and are used interchangeably. Generally, two completely complementary or substantially complementary nucleic acid sequences can hybridize or anneal. The complementarity required for two nucleic acid sequences to hybridize or anneal depends on the hybridization conditions used, particularly the temperature.

[0107] As used herein, “conditions that allow nucleic acid hybridization” has the meaning commonly understood by those skilled in the art and can be determined by conventional methods. For example, two nucleic acid molecules with complementary sequences can hybridize under suitable hybridization conditions. Such hybridization conditions may involve factors such as temperature, pH, composition, and ionic strength of the hybridization buffer, and can be determined based on the lengths and GC contents of the two complementary nucleic acid molecules. For example, low-tightness hybridization conditions may be used when the lengths of the two complementary nucleic acid molecules are relatively short and / or the GC contents are relatively low. High-tightness hybridization conditions may be used when the lengths of the two complementary nucleic acid molecules are relatively long and / or the GC contents are relatively high. Such hybridization conditions are well known to those skilled in the art and can be found, for example, in Joseph Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001); and MLM Anderson, Nucleic Acid Hybridization, Springer-Verlag New York Inc. NY (1999). In this application, “hybridization” and “annealing” have the same meaning and are used interchangeably. Correspondingly, the expressions "conditions that allow nucleic acid hybridization" and "conditions that allow nucleic acid annealing" have the same meaning and can be used interchangeably.

[0108] As used herein, the phrase "conditions that allow nucleic acid amplification" has the meaning commonly understood by those skilled in the art as referring to conditions that allow a nucleic acid polymerase (e.g., DNA polymerase) to synthesize another nucleic acid strand using one nucleic acid strand as a template, forming a double helix. Such conditions are well known to those skilled in the art and may involve factors such as temperature, pH, composition, concentration, and ionic strength of the hybridization buffer. Suitable nucleic acid amplification conditions can be determined using conventional methods (see, for example, Joseph Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001)). In the method of this invention, "conditions that allow nucleic acid amplification" preferably refers to the operating conditions of the nucleic acid polymerase (e.g., DNA polymerase).

[0109] As used herein, the term "melting curve analysis" has the meaning commonly understood by those skilled in the art, referring to the method of analyzing the presence or identity of double-stranded nucleic acid molecules by measuring their melting curves, typically used to assess the dissociation characteristics of double-stranded nucleic acid molecules during heating. Methods for performing melting curve analysis are well known to those skilled in the art (see, for example, The Journal of Molecular Diagnostics 2009, 11(2): 93-101). In this application, the terms "melting curve analysis" and "melting analysis" have the same meaning and are used interchangeably.

[0110] In certain preferred embodiments of this application, melting curve analysis can be performed using detection probes labeled with reporter and quencher groups. In short, at ambient temperature, the detection probe forms a double strand with its complementary sequence through base pairing. In this case, the reporter group (e.g., a fluorophore) and quencher group on the detection probe separate from each other, and the quencher group cannot absorb the signal emitted by the reporter group (e.g., a fluorescent signal), at which point the strongest signal (e.g., a fluorescent signal) can be detected. As the temperature increases, the two strands of the double strand begin to dissociate (i.e., the detection probe gradually dissociates from its complementary sequence), and the dissociated detection probe is in a single-stranded, freely coiled state. In this case, the reporter group (e.g., a fluorophore) and quencher group on the dissociated detection probe approach each other, thereby the signal emitted by the reporter group (e.g., a fluorophore) (e.g., a fluorescent signal) is absorbed by the quencher group. Therefore, as the temperature increases, the detected signal (e.g., a fluorescent signal) gradually weakens. When the two strands of the double strand are completely dissociated, all detection probes are in a single-stranded, freely coiled state. In this case, the signals (e.g., fluorescence signals) emitted by all reporter groups (e.g., fluorescent groups) on the detection probe are absorbed by the quenching groups. Therefore, the signals (e.g., fluorescence signals) emitted by the reporter groups (e.g., fluorescent groups) are essentially undetectable. Therefore, by detecting the signals (e.g., fluorescence signals) emitted by the duplex containing the detection probe during heating or cooling, the hybridization and dissociation processes between the detection probe and its complementary sequence can be observed, forming a curve showing the signal intensity changing with temperature. Further, by performing derivative analysis on the obtained curve, a curve with the rate of change of signal intensity as the ordinate and temperature as the abscissa (i.e., the melting curve of the duplex) can be obtained. The peaks in this melting curve are the melting peaks, and the corresponding temperatures are the melting points of the duplex. T m Value). Generally speaking, the higher the match between the detection probe and the complementary sequence (e.g., fewer mismatched bases and more paired bases), the stronger the double strand. T m The higher the value, the better. Therefore, by detecting the double strand...T m The value can determine the presence and identity of the sequence complementary to the detection probe in the duplex. In this paper, the terms "melting peak," "melting point," and "[missing information]" are used interchangeably. T m The terms "value" and "value" have the same meaning and can be used interchangeably.

[0111] As used herein, the term “PCR reaction” has the meaning commonly understood by those skilled in the art as referring to a reaction (polymerase chain reaction) in which nucleic acid polymerases and primers are used to amplify target nucleic acids.

[0112] As used herein, the term "identity" refers to the sequence matching between two polypeptides or two nucleic acids. To determine the percentage identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., a gap may be introduced in the first amino acid sequence or nucleic acid sequence to best align with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecule is identical at that position. The percentage identity between two sequences is a function of the number of identity positions shared by the sequences (i.e., percentage identity = number of identical overlapping positions / total number of positions × 100%). In some embodiments, the two sequences are of the same length.

[0113] Beneficial effects This application provides a probe suite for single-reaction detection of five HIV drug resistance mutations. Compared to Sanger sequencing, the gold standard, the detection method using this probe suite exhibits significantly improved sensitivity, capable of detecting mutation templates as low as 200 copies / ml; the ability to identify low-abundance mutations is greatly enhanced, accurately identifying drug resistance prespecies with abundances as low as 1%–5%, representing improvements of at least 5–10 times and at least 4–20 times compared to Sanger sequencing, respectively. It is particularly suitable for detecting HIV drug resistance mutations in patients with low viremia.

[0114] Meanwhile, the probe combination of this application exhibits superior detection performance compared to multiple probe combinations targeting the same target. On one hand, the probe combination of this application can detect clear, sharp, and completely separated melting curve signals for all five covered drug resistance mutations, and the peak heights of the melting curves are superior to other probe combinations, significantly improving the sensitivity of the detection system. On the other hand, the probe combination of this application can more effectively avoid or even eliminate mutual interference between probes and between probes and primers, and will not generate non-specific melting curve signals that affect result interpretation in any region, effectively improving the specificity of the detection system. Therefore, the probe combination of this application significantly improves the overall detection performance of the system.

[0115] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings and examples. However, those skilled in the art will understand that the following drawings and examples are for illustrative purposes only and are not intended to limit the scope of the invention. Various objects and advantages of the present invention will become apparent to those skilled in the art from the following detailed description of the drawings and preferred embodiments. Attached Figure Description

[0116] Figure 1 Examples showing hybridization of the mediator probe and the target sequence ( Figure 1 Example of structure of A) and detection probe (in the image) Figure 1 (B) Taking the first mediator probe as an example, the first mediator probe contains a mediator sequence and a target-specific sequence from the 5' to 3' direction, with the target-specific sequence binding complementary to the target sequence. The first detection probe contains a reporter group and a quencher group, and is a self-quenching probe. When the target sequence is present, the target-specific sequence of the first mediator probe binds to the target sequence. Under the action of an enzyme with 5' nuclease activity, as the upstream sequence extends, the mediator sequence in the first mediator probe can be cleaved from the mediator probe, forming a free mediator fragment. Subsequently, the mediator sequence can hybridize to the detection probe and be extended by a nucleic acid polymerase, thereby producing an extension product, which together with the detection probe forms a double strand with a specific Tm value, and the reporter group and quencher group are separated from each other, so that the signal emitted by the reporter group cannot be absorbed by the quencher group, thereby enabling the detection probe to emit a signal.

[0117] Figure 2 This demonstrates the detection performance of different medium probes designed for the I47A site.

[0118] Figure 3 This demonstrates the detection performance of different medium probes designed for the I50L site.

[0119] Figure 4 This demonstrates the detection performance of different media probes designed for the I84V site.

[0120] Figure 5 This demonstrates the detection performance of different medium probes designed for the N88S site.

[0121] Figure 6 This demonstrates the detection performance of different medium probes designed for the G118R site.

[0122] Figure 7 This shows the detection results of five mutations using different probe combinations in a single-reaction assay.

[0123] Figure 8The results of single-reaction assays show the detection results of five mutations using the probe combinations I47A-P8, I50L-P8, I84V-P15, N88S-P10, and G118R-P12.

[0124] Figure 9 The demonstration medium probe combinations I47A-P8, I50L-P8, I84V-P15, N88S-P10, and G118R-P12 demonstrate their ability to detect low-abundance templates.

[0125] Figure 10 This demonstrates the detection capabilities of the medium probe assemblies I47A-P8, I50L-P8, I84V-P15, N88S-P10, and G118R-P12 for low-copy templates.

[0126] Sequence information Information regarding a portion of the sequence involved in this invention is provided below.

[0127]

[0128]

[0129] The symbols Y, M, H, and R in the sequence are for mix-bases, representing a mixture of two or more bases. Specifically, Y = C / T; M = A / C; H = A / C / T; R = A / G; and W = A / T. Detailed Implementation

[0130] The invention will now be described with reference to the following examples, which are intended to illustrate the invention (and not limit it). Unless otherwise specified, the molecular biology experimental methods and immunoassays used in this invention are substantially in accordance with the methods described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FM Ausubel et al., A Concise Guide to Laboratory Molecular Biology, 3rd Edition, John Wiley & Sons, Inc., 1995.

[0131] Furthermore, unless specific conditions are specified in the examples, conventional conditions or conditions recommended by the manufacturer should be followed. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products. Those skilled in the art will understand that the examples are described by way of illustration and are not intended to limit the scope of protection claimed by the invention. All disclosures and other references mentioned herein are incorporated herein by reference in their entirety.

[0132] Example 1. Single-selection experiment using four highly drug-resistant mutations in HIV protease and one highly drug-resistant mutation in HIV integrase. With the widespread use of antiretroviral therapy, HIV drug resistance mutations have become a core cause of treatment failure. Protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) are the backbone of current anti-HIV treatment regimens, and early and accurate detection of their resistance mutations is crucial for personalized medication. The Stanford HIV Resistance Database assigns a weighted score to each resistance mutation, defining "high-level resistance" as a cumulative score ≥60, signifying complete loss of drug activity. A single mutation score of 60 represents the most severe degree of resistance to the corresponding drug. Therefore, a resistance mutation score of 60 has the highest clinical warning value as a detection biomarker. This invention focuses on four key mutations with a score of 60 in PI drugs—mutations I47A, I50L, I84V, and N88S encoding the HIV protease (SEQ ID NO: 1) in the PR region (nucleotide sequence shown in SEQ ID NO: 2) and G118R encoding the HIV integrase (SEQ ID NO: 3) in the INT region (nucleotide sequence shown in SEQ ID NO: 4)—a key mutation with a score of 60 in INSTI drugs. Specifically: I47A is highly resistant to lopinavir / ritonavir (LPV / r); I50L, I84V, and N88S are all highly resistant to atazanavir / ritonavir (ATV / r); G118R is highly resistant to both dolutegravir (DTG) and capecitabine (CAB), and also exhibits moderate to high resistance to bilutegravir (BIC), demonstrating broad cross-resistance characteristics. In summary, the five selected mutations are all high-level drug resistance mutations with a Stanford score of 60, covering two core drug classes: PIs and INSTIs. They are highly representative in terms of the breadth of drug resistance spectrum and treatment guidance value. The detection system established for them can provide efficient evidence for precision antiviral treatment.

[0133] The detection in this application is based on MeltArray melting array technology, combined with PCR and melting curve analysis, and uses media probes and detection probes to detect HIV drug resistance mutations.

[0134] like Figure 1 As shown, the vector probe contains a vector subsequence and a target-specific sequence from the 5' to 3' direction. The target-specific sequence contains a sequence complementary to the mutant target sequence of the HIV drug resistance mutation site. The vector subsequence contains a sequence that is not complementary to the mutant target sequence. Furthermore, the vector subsequences contained in all vector probes may be different from or the same as each other. Each detection probe independently includes, from the 3' to 5' direction, a capture sequence complementary to or partially complementary to the mediator subsequence, and a template sequence; and the capture sequence is complementary to or partially complementary to the mediator subsequence of the mediator probe; and each detection probe is independently labeled with a reporter group and a quencher group, wherein the reporter group is capable of emitting a signal, and the quencher group is capable of absorbing or quenching the signal emitted by the reporter group; and the signal emitted by each detection probe when hybridizing with its complementary sequence is different from the signal emitted when it does not hybridize with its complementary sequence.

[0135] Therefore, when a mutant target sequence containing a specific HIV drug resistance mutation site is present, both the upstream primer and the mediator probe corresponding to the mutant target sequence hybridize with the target nucleic acid sequence. However, the mediator sequence in the mediator probe remains in a free state and does not hybridize with the target nucleic acid sequence. In this case, under the action of an enzyme with 5' nuclease activity, the mediator sequence or a portion thereof in the mediator probe (the mediator probe corresponding to the target nucleic acid sequence) is cleaved from the mediator probe due to the presence of the upstream primer or its extension product corresponding to the target nucleic acid sequence, forming a mediator fragment corresponding to the target nucleic acid sequence.

[0136] Therefore, when a mediator fragment corresponding to the mutant target sequence is present, the mediator fragment hybridizes with the detection probe, and the nucleic acid polymerase extends the mediator fragment using the detection probe as a template to form a double-stranded structure corresponding to the target nucleic acid sequence. Furthermore, when a melting peak corresponding to a double-stranded structure corresponding to a certain target nucleic acid sequence is detected or not detected, it is determined that the target nucleic acid sequence is present or not present in the sample.

[0137] In this embodiment, several vector probes were designed for each mutation site for single-stage screening. Wild-type and corresponding mutant plasmids were used as templates during screening, and NTC was set as a negative control. Probes with good mutation signals and no melting signal in the wild-type template and NTC (no template control) were ultimately selected for subsequent merging.

[0138] Experimental procedure: The reaction was performed in 25 μL solution. The reaction components included PCR buffer, 3 mM MgCl2, 0.2 mM dNTPs, 1 U Taq DNA polymerase (Zeesan Biotech), and 5 μL cDNA template (the sequences of the PR and INT regions were ligated into the pUC57 vector to construct plasmid templates). The reaction included target-specific primers, vector probes, and detection probes (molecular beacon probes) corresponding to the screened mutation sites. PCR and melting curve analysis were performed using a SLAN 96S real-time PCR instrument. The reaction program was as follows: 95°C for 2 min; 45 cycles: 95°C for 15 s, 58°C for 45 s; 35°C for 30 min; 95°C for 2 min; 45°C for 2 min; then the temperature was increased from 45°C to 95°C (0.08 °C / s). During the temperature increase, changes in the fluorescence intensity of the FAM, HEX, and ROX channels were detected, and the melting point value was output by software.

[0139] The target-specific primers for amplifying the PR region are shown in SEQ ID NO: 5 and 6, and the target-specific primers for amplifying the INT region are shown in SEQ ID NO: 7 and 8. The nucleotide sequences of the universal detection probes FAM-P1 (detection) and FAM-P2 are shown in SEQ ID NO: 9 and 10, respectively, with the FAM group attached to their 5' end and the BHQ1 group attached to their 3' end; the nucleotide sequences of HEX-P1 and HEX-P2 are shown in SEQ ID NO: 11 and 12, respectively, with the HEX group attached to their 5' end and the BHQ1 group attached to their 3' end; the nucleotide sequence of ROX-P is shown in SEQ ID NO: 13, with the ROX group attached to their 5' end and the BHQ2 group attached to their 3' end.

[0140] The probes designed for single-selection at the HIV protease I47A site, along with their melting points and sequence information, are as follows: Probe Name SEQ ID NO: Melting point I47A-P1 14 57.82±1℃ I47A-P2 15 76.79±1℃ I47A-P3 16 64.03±1℃ I47A-P4 17 74.39±1℃ I47A-P5 18 74.39±1℃ I47A-P6 19 74.39±1℃ I47A-P7 20 74.39±1℃ I47A-P8 21 57.82±1℃ I47A-P9 22 82.66±1℃ I47A-P10 23 74.33±1.5℃ The results are as follows Figure 2 As shown in the figure, the gray curve represents NTC, the black curve represents the wild-type plasmid template, and the other colored curves represent the mutant plasmid template. Different colors represent different fluorescence channel screening results: FAM channel is blue, HEX channel is green, ROX channel is orange, and Cy5 channel is red. The results show that probes I47A-P8, I47A-P9, and I47A-P10 all have good reaction intensity and specificity, and do not bind to the unmutated wild-type plasmid. However, probes I47A-P2, I47A-P4, I47A-P6, and I47A-P7 also show high binding levels to the wild-type plasmid template, indicating poor probe specificity and an inability to distinguish between wild-type and mutant templates.

[0141] The probes designed for single-screening at the HIV protease I50L site, along with their melting points and sequence information, are as follows: Probe Name SEQ ID NO: Melting point I50L-P1 24 81.33±1℃ I50L-P2 25 82.96±1℃ I50L-P3 26 84.86±1℃ I50L-P4 27 71.65±1℃ I50L-P5 28 79.01±1℃ I50L-P6 29 77.64±1℃ I50L-P7 30 84.50±1℃ I50L-P8 31 79.01±1℃ The results are as follows Figure 3 As shown in the figure, the gray curve represents NTC, the black curve represents the wild-type plasmid template, and the other colored curves represent the mutant plasmid template. Different colors represent different fluorescence channel screening results: FAM channel is blue, HEX channel is green, ROX channel is orange, and Cy5 channel is red. The results show that probes I50L-P3 and I50L-P8 have good reaction intensity and specificity, and do not bind to the unmutated wild-type plasmid. However, probes I50L-P1 and I50L-P4 have extremely low detection signal intensity, possibly due to low binding levels and poor binding stability between the mutant template and the probe. I50L-P5 shows obvious wild-type plasmid template signal and background signal, indicating that the probe may have formed probe dimers, thus generating background noise. I50L-P6 exhibits non-specific bulges at non-target peaks, possibly due to non-specific cleavage of the mediator or non-specific hybridization of the mediator sequence on the detection probe.

[0142] The probes designed for single-screening at the HIV protease I84V site, along with their melting points and sequence information, are as follows: Probe Name SEQ ID NO: Melting point I84V-P1 32 77.64±1℃ I84V-P2 33 84.05±1℃ I84V-P3 34 74.33±1.5℃ I84V-P4 35 74.33±1.5℃ I84V-P5 36 84.50±1℃ I84V-P6 37 70.28±1℃ I84V-P7 38 67.34±1℃ I84V-P8 39 64.58±1℃ I84V-P9 40 70.05±1℃ I84V-P10 41 61.28±1℃ I84V-P11 42 66.94±1℃ I84V-P12 43 70.28±1℃ I84V-P13 44 76.79±1℃ I84V-P14 45 84.50±1℃ I84V-P15 46 67.49±1℃ I84V-P16 47 82.96±1℃ The results are as follows Figure 4 As shown in the figure, the gray curve represents NTC, the black curve represents the wild-type plasmid template, and the other colored curves represent the mutant plasmid template. Different colors represent different fluorescence channel screening results: FAM channel is blue, HEX channel is green, ROX channel is orange, and Cy5 channel is red. The results indicate that probes I84V-P15 and I84V-P16 both exhibit good reaction intensity and specificity, and do not bind to the unmutated wild-type plasmid.

[0143] The probes designed for single-selection at the N88S site of the HIV protease, along with their melting points and sequence information, are as follows: Probe Name SEQ ID NO: Melting point N88S-P1 48 64.58±1℃ N88S-P2 49 64.58±1℃ N88S-P3 50 84.50±1℃ N88S-P4 51 84.50±1℃ N88S-P5 52 79.01±1℃ N88S-P6 53 79.01±1℃ N88S-P7 54 70.28±1℃ N88S-P8 55 66.57±1℃ N88S-P9 56 64.49±1℃ N88S-P10 57 84.86±1℃ The results are as follows Figure 5 As shown in the figure, the gray curve represents NTC, the black curve represents the wild-type plasmid template, and the other colored curves represent the mutant plasmid template. Different colors represent different fluorescence channel screening results: FAM channel is blue, HEX channel is green, ROX channel is orange, and Cy5 channel is red. The results indicate that probes N88S-P9 and N88S-P10 both exhibit good reaction intensity and specificity, and do not bind to the unmutated wild-type plasmid.

[0144] The probes designed for single-selection at the HIV integrase G118R site, along with their melting points and sequence information, are as follows: Probe Name SEQ ID NO: Melting point G118R-P1 58 74.39±1℃ G118R-P2 59 74.39±1℃ G118R-P3 60 64.49±1℃ G118R-P4 61 84.05±1℃ G118R-P5 62 74.33±1.5℃ G118R-P6 63 75.86±1℃ G118R-P7 64 82.66±1℃ G118R-P8 65 84.86±1℃ G118R-P9 66 70.28±1℃ G118R-P10 67 70.28±1℃ G118R-P11 68 85.7±1℃ G118R-P12 69 70.39±1℃ G118R-P13 70 79.01±1℃ G118R-P14 71 84.50±1℃ The results are as follows Figure 6 As shown in the figure, the gray curve represents NTC, the black curve represents the wild-type plasmid template, and the other colored curves represent the mutant plasmid template. Different colors represent different fluorescence channel screening results: FAM channel is blue, HEX channel is green, ROX channel is orange, and Cy5 channel is red. The results indicate that probes G118R-P12, G118R-P13, and G118R-P14 all exhibit good reaction intensity and specificity, and do not bind to the unmutated wild-type plasmid.

[0145] Example 2. Multiplex detection of five drug resistance mutations using different probe combinations Based on the results of Example 1, we selected probes that can effectively achieve single detection and formed a variety of probe combinations. By comparing the detection effects of different probe combinations, we obtained the optimal probe combination (final version) for simultaneously detecting I47A, I50L, I84V, N88S mutations of HIV protease and G118R mutation of HIV integrase.

[0146] Experimental Procedure: A single reaction was performed to detect the five drug resistance mutations mentioned above, with the reaction carried out in 25 μL solution. The reaction components included PCR buffer, 3 mM MgCl2, 0.2 mM dNTPs, 1 U Taq DNA polymerase (Zeesan Biotech), and 5 μL cDNA template (the sequences of the PR and INT regions were ligated into the pUC57 vector to construct plasmid templates, respectively). The reaction included two pairs of target-specific primers, five mediator probes, and a detection probe (the target-specific primers and detection probes were the same as in Example 1; the specific mediator probes used in different probe combinations are shown in Table 1). PCR and melting curve analysis were performed using a SLAN 96S real-time PCR instrument. The reaction program was as follows: 95°C for 2 min; 45 cycles: 95°C for 15 s, 58°C for 45 s; 35°C for 30 min; 95°C for 2 min; 45°C for 2 min; then the temperature was increased from 45°C to 95°C (0.08 °C / s). During the temperature increase, the changes in fluorescence intensity of the FAM, HEX, and ROX channels were detected, and the melting point value was output by the software.

[0147] Table 1: Medium probes used in different probe combinations: resistance sites Final version of the system solution Merger Plan 1 Merger Option 2 Merger Plan 3 Merger Plan 4 I47A I47A-P8 I47A-P9 I47A-P10 I47A-P8 I47A-P8 I50L I50L-P8 I50L-P3 I50L-P8 I50L-P8 I50L-P8 I84V I84V-P15 I84V-P16 I84V-P15 I84V-P16 I84V-P15 N88S N88S-P10 N88S-P9 N88S-P10 N88S-P9 N88S-P10 G118R G118R-P12 G118R-P13 G118R-P12 G118R-P12 G118R-P14 The results are as follows Figure 7 and Figure 8As shown, the final version of the system has high intensity of each mutation signal, clear and sharp signal peaks, and complete separation. There are no non-specific signals in wild-type template and NTC, no other non-target peaks, and only three fluorescence channels, FAM, HEX and ROX, are required, making it compatible with almost all conventional real-time PCR instruments.

[0148] The merging schemes 1-4 suffer from issues such as overlapping signal peaks, weak signal intensity, and the need for additional signal channels. These factors all affect detection performance to varying degrees, thus impacting the interpretation of detection results. The possible reasons for these problems with merging schemes 1-4 are twofold: First, the mutation sites being detected simultaneously are relatively close (e.g., sites 47 and 50; sites 84 and 88), which can easily lead to non-specific binding between the vector probe and the target nucleic acid, or even between vector probes themselves, or competition between vector probes for the target nucleic acid sequence, resulting in reduced binding efficiency. Second, the melting peak temperatures of vector probes that have successfully undergone single-selection at different mutation sites are too close together, leading to competitive binding and extension of the vector subsequence on the detection probe, thus suppressing the melting peak signal.

[0149] In the final version of the system, probe combination I47A-P8 (SEQ ID NO: 21) can hybridize with detection probe FAM-P1 (SEQ ID NO: 9), I50L-P8 (SEQ ID NO: 31) can hybridize with detection probe ROX-P (SEQ ID NO: 13), I84V-P15 (SEQ ID NO: 46) can hybridize with detection probe HEX-P1 (SEQ ID NO: 11), N88S-P10 (SEQ ID NO: 57) can hybridize with detection probe HEX-P2 (SEQ ID NO: 12), and G118R-P12 (SEQ ID NO: 69) can hybridize with detection probe FAM-P2 (SEQ ID NO: 10).

[0150] Example 3. Evaluation of the detection capability of probe assemblies for low-abundance templates This embodiment evaluates the detection capability of probe combinations I47A-P8, I50L-P8, I84V-P15, N88S-P10, and G118R-P12 for low-abundance templates. The experimental procedure is described in Example 2. Specifically, to evaluate the system's ability to detect low-abundance mutations, mixed templates of different ratios of mutant plasmids and wild-type plasmids were prepared in advance at a template concentration of 2000 copies / µL, including 100%, 50%, 20%, 10%, 5%, 2%, and 1%. Each ratio of mixed template was tested three times. The lowest mixing ratio that produced a mutation signal in all three tests and was clearly distinguishable from the wild-type template signal was the lowest mutation detection abundance of the system.

[0151] The results of the investigation show that ( Figure 9 The probe combination described above, at a template concentration of 2000 copies / µL (total concentration 10000 copies / reaction), showed minimum detectable abundances of five mutations: I47A (5%), I50L (1%), I84V (1%), N88S (1%), and G118R (5%). Sanger sequencing technology can only detect ≥20% abundance of quasi-drug-resistant HIV mutations. Using the probe combination described in this application to detect HIV drug resistance mutations, the ability to identify quasi-drug-resistant HIV mutations is improved from 20% to 1%–5%, which is 4–20 times that of Sanger sequencing. Therefore, the probe combination described in this application can effectively detect drug-resistant viral mutations carried by patients with low-level viremia (LVV), and can also provide accurate detection in the early stages of drug-resistant virus infection in AIDS patients, helping to adjust treatment plans in a timely manner, preventing drug-resistant strains from evolving into dominant strains under drug selection pressure, and contributing to improved treatment efficiency.

[0152] Example 4. Evaluation of the detection sensitivity of the probe combination This embodiment evaluates the detection capability of probe combinations I47A-P8, I50L-P8, I84V-P15, N88S-P10, and G118R-P12 for low-copy templates. The experimental procedure is the same as in Example 2. To evaluate the system's ability to detect low-copy mutations, the detection signal intensity of the probe combinations was tested at template amounts of 10,000 copies / reaction, 1,000 copies / reaction, 100 copies / reaction, and 10 copies / reaction, as well as their signal differentiation from wild-type templates.

[0153] The results of the minimum detection limit (LOD) study show that ( Figure 10 Within a concentration range of 10-10000 copies / reaction, each mutation site exhibited a normal melting peak signal in 20 replicate reactions. Therefore, the LOD of all five mutation sites in the system was 10 copies / reaction.

[0154] After evaluating the performance of the system at five mutation sites using plasmids, we selected two mutations, I47A and I50L, to construct a pseudovirus for further evaluation of the system's Level of Detection (LOD) to simulate the analytical performance during real sample detection. The pseudoviruses containing the I47A and I50L mutation sites were diluted to 2000, 1000, 500, and 200 copies / mL. Viral RNA extraction was performed using the Lab-Aid 824 viral nucleic acid extraction system (Zeesan Biotech), with a loading volume of 1 mL and an elution volume of 100 μL. The extracted RNA was then used to obtain RT-PCR products using a one-step RT-PCR kit (Takara Biomedical Technology). The RT-PCR products obtained from the different concentrations of RNA were then detected using the MeltArray HIVDR system. Each template concentration was tested 20 times, and the lowest concentration achieving a 95% positive detection rate at the mutation sites was considered the LOD. The results (Table 2) show that when detecting the one-step RT-PCR products of the pseudovirus, the LOD at the two mutation sites could be reduced to 200 copies / mL.

[0155] The sensitivity of Sanger sequencing technology for detecting HIV drug resistance mutations is between 1000-2000 copies / ml. When using the probe suite of this application to detect HIV drug resistance mutations, it can detect viral loads as low as 200 copies / ml. Therefore, the probe suite of this application can effectively detect drug resistance mutations carried by patients with low viremia and can also provide early intervention for patients with low viral loads, helping to curb the spread of HIV.

[0156] Table 2: Results of the LOD (Level of Detection) Study of Pseudoviruses

[0157] Although specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and variations can be made to the details based on all the published teachings, and all such changes are within the scope of protection of the present invention. The full scope of protection of the present invention is given by the appended claims and any equivalents thereof.

Claims

1. A probe combination, characterized in that The probe assembly includes the following medium probes: The first mediator probe has the nucleotide sequence shown in SEQ ID NO: 21; The second medium probe has the nucleotide sequence shown in SEQ ID NO: 31; The third medium probe has the nucleotide sequence shown in SEQ ID NO: 46; The fourth mediator probe has the nucleotide sequence shown in SEQ ID NO: 57; The fifth medium probe has the nucleotide sequence shown in SEQ ID NO:

69.

2. The probe combination of claim 1, wherein The mediator probe comprises a mediator subsequence and a target-specific sequence from the 5' to 3' direction. The mediator subsequence contains a sequence that is not complementary to the target nucleic acid sequence, and the target-specific sequence contains a sequence that is complementary to the target nucleic acid sequence. The probe assembly has one or more of the following technical features: (1) The target-specific sequence of the first mediator probe contains a sequence complementary to the region encoding the HIV protease containing the I47A mutation. (2) The target-specific sequence of the second medium probe contains a sequence complementary to the region encoding the HIV protease containing the I50L mutation; (3) The target-specific sequence of the third mediator probe contains a sequence complementary to the region encoding the HIV protease containing the I84V mutation; (4) The target-specific sequence of the fourth mediator probe contains a sequence complementary to the region encoding the HIV protease containing the N88S mutation; (5) The target-specific sequence of the fifth mediator probe contains a sequence complementary to the region encoding the HIV integrase containing the G118R mutation.

3. A kit comprising the probe combination of claim 1 or 2.

4. The kit of claim 3, wherein The kit also includes one or more components selected from the following: nucleic acid polymerase, reagents for nucleic acid amplification, reagents for sequencing, reagents for melting curve analysis, or any combination thereof.

5. The kit of claim 3, wherein The kit includes: a first detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the first media probe; a second detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the second media probe; a third detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the third media probe; a fourth detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the fourth media probe; and a fifth detection probe containing a capture sequence complementary to a media sub-sequence or a portion thereof of the fifth media probe; wherein the detection probe has one or more of the following technical features: (1) The nucleotide sequence of the first detection probe is shown in SEQ ID NO: 9; (2) The nucleotide sequence of the second detection probe is shown in SEQ ID NO: 13; (3) The nucleotide sequence of the third detection probe is shown in SEQ ID NO: 11; (4) The nucleotide sequence of the fourth detection probe is shown in SEQ ID NO: 12; (5) The nucleotide sequence of the fifth detection probe is shown in SEQ ID NO:

10.

6. The kit of claim 5, wherein The detection probe has one or more of the following technical features: (1) The fluorescent group connected to the first detection probe is FAM, and the quenching group connected to it is BHQ1; (2) The fluorescent group connected to the second detection probe is ROX, and the quenching group connected to it is BHQ2; (3) The fluorescent group connected to the third detection probe is HEX, and the quenching group connected to it is BHQ1; (4) The fluorescent group connected to the fourth detection probe is HEX, and the quenching group connected to it is BHQ1; (5) The fluorescent group connected to the fifth detection probe is FAM, and the quenching group connected to it is BHQ1.

7. The kit of claim 3, wherein The kit also includes primers for amplifying nucleotide sequences of regions containing I47A mutations, regions containing I50L mutations, regions containing I84V mutations, regions containing N88S mutations, and / or regions containing G118R mutations in HIV integrase.

8. The kit of claim 3, wherein The kit also contains primers for amplifying the nucleotide sequence encoding the HIV protease and / or primers for amplifying the nucleotide sequence encoding the HIV integrase.

9. The kit of claim 8, wherein The sequences of the primers used to amplify the nucleotide sequence encoding the HIV protease are shown in SEQ ID NO: 5 and SEQ ID NO: 6; and / or, the sequences of the primers used to amplify the nucleotide sequence encoding the HIV integrase are shown in SEQ ID NO: 7 and SEQ ID NO:

8.

10. Use of a probe combination according to claim 1 or 2 or a kit according to any one of claims 3 to 9 for the manufacture of a reagent, characterized in that, The reagent is used to detect whether a subject carries drug-resistant HIV or to detect the level of drug-resistant HIV carried by the subject; the drug-resistant HIV contains one or more mutations selected from the following: HIV protease mutations I47A, I50L, I84V, N88S and HIV integrase mutation G118R.

11. Use according to claim 10, characterized in that, The subjects were patients with low viremia.

Citation Information

Patent Citations

  • A method for detecting target nucleic acid sequences

    CN108823287B

  • Fluorescence quenching with immunological pairs in immunoassays

    US3996345A

  • Novel alkyl substituted fluorescent compounds and polyamino acid conjugates

    US4351760A